Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds

Introduction. Given its efficacy and safety, NexoBrid™ (NXB) has become part of our therapeutic options in burns treatment with satisfactory results. However, no cost analysis comparing NXB to the standard of care (SOC) has been carried out as of today. Aim. To assess the cost of treatment with NXB...

Descripción completa

Detalles Bibliográficos
Autores principales: Giudice, Giuseppe, Filoni, Angela, Maggio, Giulio, Bonamonte, Domenico, Vestita, Michelangelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331316/
https://www.ncbi.nlm.nih.gov/pubmed/28293640
http://dx.doi.org/10.1155/2017/9567498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331316/
https://www.ncbi.nlm.nih.gov/pubmed/28293640
http://dx.doi.org/10.1155/2017/9567498

Ejemplares similares